Afatinib dimaleate
|
- ₹0
- Product name: Afatinib dimaleate
- CAS: 850140-73-7
- MF: C28H29ClFN5O7
- MW: 602.02
- EINECS:810-416-1
- MDL Number:MFCD28969755
- Synonyms:BIBW2992 DiMaleate;BIBW2992-MA2;Afatinib (diMaleate), BIBW2992;2-ButenaMide, N-[4-[(3-chloro-4-fluorophenyl)aMino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(diMethylaMino)-, (2E)-, (2Z)-2-butenedioate (1:2);(2E)-N-(4-[(3-chloro-4-fluorophenyl)aMino]-7-{[(3S);Afatinib double Maleate;Afatinib (BIBW2992) Dimaleate;N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-(2E)-2-butenamide,(2Z)-2-butenedioate (1:2)
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :>237oC (dec.)
storage temp. :Refrigerator
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
color :White to Pale Yellow
InChIKey :LIENDGDDWJRJLO-LBXKZPGENA-N
SMILES :C(/C(=O)O)=C/C(=O)O.N(C1C=CC(F)=C(Cl)C=1)C1=NC=NC2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC1=2 |&1:25,r|
storage temp. :Refrigerator
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
color :White to Pale Yellow
InChIKey :LIENDGDDWJRJLO-LBXKZPGENA-N
SMILES :C(/C(=O)O)=C/C(=O)O.N(C1C=CC(F)=C(Cl)C=1)C1=NC=NC2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC1=2 |&1:25,r|
Safety Information
| Symbol(GHS): |
 
|
||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
Afatinib dimaleate was approved by the U.S. Food and Drug Administration (FDA) in 2013 for the treatment of non-small cell lung cancer (NSCLC). Specifically, it was approved for patients presenting with metastatic NSCLC tumors which contain epidermal growth factor receptor (EGFR) exon deletions or exon 21 mutations. Afatinib dimaleate is a covalent inhibitor of ErbB tyrosine kinases (tyk), which downregulates ErbB signaling by irreversible binding of EGFR tyk binding sites. While no manufacturing route has been disclosed to date, the most scalable published route likely derives from two Boehringer Ingelheim patents.More related product prices
4-QuinazolinaMine, N-(3-chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]- 162012-69-3 Afatinib (BIBW 2992) 86087-23-2 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro- Afatinib (S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine trans-4-Dimethylaminocrotonic acid hydrochloride Olaparib Nintedanib Ethanesulfonate Salt 918504-65-1 PLERIXAFOR CrizotinibRelated product price
- 162012-69-3
₹6100 - 86087-23-2
₹2231-21909.8 - 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-
₹4400-12000